News | Prostate Cancer | December 14, 2016

Cancer Targeted Technology Commences Phase I Clinical Trial of Prostate Cancer Imaging Agent

Trial will evaluate safety and tolerability of PET agent that binds to PSMA with enhanced uptake and internalization

December 14, 2016 — Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced a Phase I clinical trial has commenced in men with high-risk metastatic prostate cancer. In late August, the U.S. Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a positron emission tomography (PET) imaging agent, CTT1057, labeled with a two-hour half life radiolabel, fluorine-18, and targeting prostate-specific membrane antigen (PSMA).

PSMA is over-expressed on prostate cancer and this expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s phosphoramidate-based agents bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to increased accumulation of the drug and radiolabel within the tumor. The first patient in this trial was imaged in early November and the study is supported by a $2M Small Business Innovation Research (SBIR) grant.

In the trial, CTT1057 will either be used alone or with CTT’s companion radiotherapeutic drug, CTT1403, that targets metastatic prostate cancer, according to CTT CEO and SBIR principal investigator Beatrice Langston-Webster. CTT1403 is currently undergoing IND-enabling studies.”

Automated radiolabeling of the drug and the clinical trials are being conducted at the University of California, San Francisco (UCSF). The principal investigator for the clinical trial is Rahul Aggarwal, M.D. The radiolabeling is directed by UCSF collaborator Henry VanBrocklin, Ph.D., director of the Radiopharmaceutical Research Program, who worked with CTT on the initial development of CTT1057, along with Cliff Berkman, Ph.D., professor of chemistry at Washington State University, who first discovered and synthesized the drug.

VanBrocklin commented, “We are excited to initiate the clinical phase of development of this new imaging agent and look forward to the results of these key studies.”

This CTT-sponsored Phase I trial is entitled “A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA).” The primary objective of this trial is to evaluate the safety and tolerability of CTT1057. An additional endpoint includes the assessment of sensitivity and specificity of CTT1057 PET imaging on a lesion-by-lesion basis as compared with standard imaging in metastatic prostate cancer. Twenty patients will be enrolled in parallel in two cohorts: Cohort A will enroll patients with prostate cancer prior to radical prostatectomy (N = 5) and Cohort B will enroll patients with evidence of metastatic castration-resistant prostate cancer (N = 15). The study is currently enrolling and is expected to conclude in mid 2017.

For more information: www.cancertargetedtechnology.com

Related Content

An oncologist practices social distancing while talking to a cancer patient. Image courtesy of University of Michigan Rogel Cancer Center

News | Coronavirus (COVID-19) | August 07, 2020
August 7, 2020 — When COVID-19 struck, health ca
As part of an international collaboration, researchers from Aarhus University and University of Leicester have succeeded in developing a dynamic 3-D CT scanning method that shows what happens inside the body during simulated heart massage

A look inside cardiopulmonary resuscitation: A 4-D computed tomography model of simulated closed chest compression. A proof of concept. Courtesy of Kasper Hansen/Jonathan Bjerg Moeller/Aarhus University

News | Cardiac Imaging | August 07, 2020
August 7, 2020 — Rapid first aid during...
Ghost imaging approach could enable detailed movies of the heart with low-dose X-rays

Researchers developed a high-resolution X-ray imaging technique based on ghost imaging that can capture the motion of rapidly moving objects. They used it to create a movie of a blade rotating at 100,000 frames per second. Image courtesy of Sharon Shwartz, Bar-Ilan University

News | X-Ray | August 06, 2020
August 6, 2020 — Researche...
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine latera

(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine lateral sampling (requiring dithering); the filled circles show the data that are sampled without dithering.

News | Computed Tomography (CT) | July 24, 2020
July 24, 2020 — A computed tomography (CT) sca
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
Medical professionals around the world have been feeding lung X-rays into a database since the beginning of the pandemic

Pre-processing results. Image courtesy of Applied Sciences.

News | Coronavirus (COVID-19) | July 22, 2020
July 22, 2020 — Researchers from the Departme
Pioneering study, which included humans, led by Tel Aviv University researchers contradicts widespread conjectures
News | Magnetic Resonance Imaging (MRI) | July 21, 2020
July 21, 2020 — Researchers at Tel Aviv University, led by Prof.

Fig. 1 The basis of high-sensitivity SPION imaging at ultra-low magnetic fields.

(A) Magnetization of 25-nm SPIONs (green), gadolinium CA (Gd-DTPA/Magnevist, blue), and water (red) as a function of magnetic field strength (B0). (B) Magnetization as a function of magnetic field strength (B0) in the ULF (<10 mT) regime for the materials shown in (A). Superparamagnetic materials, such as SPIONs, are highly magnetized even at ULF. Paramagnetic materials, such as CAs based on gadolinium, and body tissues (which typically have diamagnetic susceptibilities close to water) have absolute magnetizations that increase linearly with field strength. Curves in (A) and (B) were reproduced from data in (3253) and reflect the magnetic moment per kilogram of compound. (C) Highly magnetized SPIONs (brown) interact with nearby 1H spins in water, shortening 1H relaxation times, and causing susceptibility-based shifts in Larmor frequency. Image courtesy of Science Advances

News | Magnetic Resonance Imaging (MRI) | July 20, 2020
July 20, 2020 — Lowering the cost of magne...